Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 1999, p. 2200-2204, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Randomized, Double-Blind Trial of an Antibiotic-Lock Technique
for Prevention of Gram-Positive Central Venous Catheter-Related
Infection in Neutropenic Patients with Cancer
Jordi
Carratalà,1,*
Jordi
Niubó,2
Alberto
Fernández-Sevilla,3
Eulalia
Juvé,3
Xavier
Castellsagué,4
Juan
Berlanga,3
Josefina
Liñares,2 and
Francesc
Gudiol1
Infectious Disease
Service,1 Microbiology
Service,2 Clinical Hematology
Service,3 and Cancer Epidemiology
Service,4 Ciutat Sanitària i
Universitària de Bellvitge, Institut Català d'Oncologia,
University of Barcelona, Barcelona, Spain
Received 2 December 1998/Returned for modification 17 May
1999/Accepted 11 June 1999
 |
ABSTRACT |
The aim of the present study was to determine the efficacy of an
antibiotic-lock technique in preventing endoluminal catheter-related infection with gram-positive bacteria in neutropenic patients with
hematologic malignancies. Patients with nontunneled, multilumen central
venous catheters were assigned in a randomized, double-blinded manner
to receive either 10 U of heparin per ml (57 patients) or 10 U of
heparin per ml and 25 µg of vancomycin per ml (60 patients), which
were instilled in the catheter lumen and which were allowed to dwell in
the catheter lumen for 1 h every 2 days. Insertion-site and hub
swabs were taken twice weekly. The primary and secondary end points of
the trial were significant colonization of the catheter hub and
catheter-related bacteremia, respectively. Significant colonization of
the catheter hub occurred in nine (15.8%) patients receiving heparin
(seven patients were colonized with Staphylococcus epidermidis, one patient was colonized with Staphylococcus
capitis, and one patient was colonized with
Corynebacterium sp.), whereas the catheter hubs of none of
the patients receiving heparin and vancomycin were colonized
(P = 0.001). Catheter-related bacteremia developed in
four (7%) patients receiving heparin (three patients had S. epidermidis bacteremia and one patient had S. capitis
bacteremia), whereas none of the patients in the heparin and vancomycin
group had catheter-related bacteremia (P = 0.05). The
times to catheter hub colonization and to catheter-related bacteremia
by the Kaplan-Meier method were longer in patients receiving heparin
and vancomycin than in patients receiving heparin alone
(P = 0.004 and P = 0.06, respectively). Our study shows that a solution containing heparin and
vancomycin administered by using an antibiotic-lock technique effectively prevents catheter hub colonization with gram-positive bacteria and subsequent bacteremia during chemotherapy-induced neutropenia in patients with hematologic malignancy.
 |
INTRODUCTION |
Central venous catheters (CVCs) have
become essential tools for the appropriate management of patients with
cancer. These devices provide reliable access for administration of
chemotherapeutic agents, blood products, parenteral nutrition, and
antibiotics, but they are also a major cause of infection
(4). Catheter-related infection causes significant morbidity
and mortality in cancer patients, particularly during episodes of
chemotherapy-induced neutropenia (6, 7, 10, 23, 28). It is
estimated that the rate of septicemia associated with noncuffed CVCs
ranges from 4 to 14 percent (18). The major pathogens that
cause these infections are the gram-positive cocci, mainly
coagulase-negative staphylococci (CoNS) (5, 29). The skin
insertion site and the catheter hub are the most important sources of
catheter colonization and subsequent catheter-related bacteremia
(11, 18). In neutropenic patients with hematologic
malignancies, the catheter hub, which is frequently manipulated by the
sanitary personnel, is a major portal of entry for organisms
(30). From the contaminated hub, the organisms migrate along
the internal surface of the catheter, where they create a bloodstream infection.
The antibiotic-lock technique (ALT) consists of filling and closing of
the catheter lumen with an antibiotic solution that acts locally and
that allows the side effects and toxicity associated with systemic
administration of antibiotics to be avoided (2). This
method, which allows delivery of a high concentration of antibiotic
inside the catheter, has been used to eradicate catheter-related bacteremia, mainly in patients receiving parenteral nutrition at home,
although no comparative randomized trials have been performed to date
(1, 15). We undertook a randomized, double-blind trial to
determine the efficacy of an ALT in preventing endoluminal catheter-related infection with gram-positive bacteria during chemotherapy-induced neutropenia in patients with hematologic malignancies. The primary and secondary end points of the trial were
significant colonization of the catheter hub and catheter-related bacteremia, respectively.
 |
MATERIALS AND METHODS |
Setting and study population.
The study was conducted at the
hematology ward of a university hospital for adults in Barcelona,
Spain. From April 1994 through March 1996, hospitalized patients with a
nontunneled, multilumen, polyurethane CVC (Arrow International, Inc.,
Reading, Pa.) in place and who were to receive chemotherapy designed to
produce severe neutropenia (<500 neutrophils per µl) were eligible
for participation in the trial. Patients were excluded if they had clinical or microbiologic evidence of infection or had a known allergy
to vancomycin. Patients already receiving antibiotics or parenteral
nutrition were also excluded. Participants gave informed consent, and
the study was approved by the Ethics Committee of our institution.
Catheter insertion and care.
Catheters were inserted into
the subclavian vein by physicians who wore masks, caps, sterile gloves,
and surgical gowns and who used large sterile drapes. Study catheters
were not exchanged over guidewires. At the time of catheter insertion,
the skin insertion site was disinfected with 4% chlorhexidine
gluconate (Hibiscrub; ICI Farma, Pontevedra, Spain), which was applied
by scrubbing for at least 30 s. The insertion sites were covered
with sterile gauze.
Catheter care included changing of the dressing, stock-cocks, and tubes
every 48 h by registered nurses, who followed maximal barrier
precautions. The insertion site was softly scrubbed with sterile gauze
saturated with normal saline and 4% chlorhexidine gluconate for at
least 30 s, rinsed with normal saline, and dried. Catheter lumens
were assessed for occlusion and were flushed with 10 ml of 0.9% sodium
chloride. In case of occlusion the lumen was flushed with either
heparin or urokinase by a soft instillation-aspiration technique to
reestablish patency. The insertion site and catheter hubs were
protected with 1% chlorhexidine pomade (Hibitane crema; ICI Farma),
dressed, and taped securely.
Study design.
Patients were randomized, on the day after
completion of the corresponding chemotherapy course, to receive in a
double-blind fashion either a solution containing heparin (Rovi, SA,
Madrid, Spain) at 10 U/ml or heparin at 10 U/ml and vancomycin (Lilly, Madrid, Spain) at 25 µg/ml. For study solution allocation a
computer-generated list of random numbers, which was available only to
the pharmacist, was used. The stability of the heparin and vancomycin
solution has been demonstrated previously (8). The hospital
pharmacy prepared the solutions on a horizontal-airflow workbench using aseptic technique by a previously described procedure (25). The two solutions were indistinguishable to medical personnel and were
dispensed in 20-ml vials that were numerically coded and that were kept
refrigerated. The code list was kept in the hospital pharmacy and was
opened only after the study was completed. The neutrophil count was
determined daily, and when it was below 500 per µl the administration
of the allocated solution was initiated. A 2.5-ml injection of the
solution was administered through the stock-cocks in each catheter
lumen and was allowed to dwell for approximately 1 h every 2 days.
In all cases, the solution was then aspirated with a syringe and was discarded.
Swabs of the skin insertion site and the inner surfaces of the catheter
hubs were obtained before randomization and twice
weekly thereafter for
culture. Swabs of the insertion site and
catheter hub as well as blood
specimens from a peripheral vein
were also obtained for culture before
the beginning of intravenous
empirical antibiotic therapy for fever and
neutropenia. Ceftazidime
plus amikacin was the empirical antibiotic
regimen most commonly
used to treat febrile episodes that occurred
during the study
period. Vancomycin was added to the regimens of
patients in whom
infection with gram-positive bacteria was initially
suspected
and also those who had not improved after initial therapy for
48 h or who worsened before that time. In case of catheter
removal,
two 5-cm segments, a proximal subcutaneous segment and the
tip,
were sampled by a sterile technique for culture. Patients were
monitored until any of the following criteria was present: recovery
from neutropenia, administration of systemic vancomycin, colonization
of the catheter hub, bacteremia caused by gram-positive bacteria,
administration of parenteral nutrition, catheter removal, or death.
The
patients' physicians and nurses, the clinical investigators,
and the
research microbiologists who processed all cultures were
blinded to
each study
group.
Microbiologic studies.
Specimens from the skin at the
insertion site (an area of approximately 4 cm2) were
obtained for culture with a moistened sterile swab (Biomedics, Madrid,
Spain), as described previously (12). The catheter hub samples were taken by repeatedly rubbing the inner surface of the hub
with a sterile cotton swab (Eurotubo; Industrias Aulabor, SA,
Barcelona, Spain) before administration of the study solution. All
samples were sent to the laboratory in transport medium and were plated
onto blood agar plates. The outer surfaces of the catheter tips were
cultured by the roll-plate technique and were rolled back and forth
across the surfaces of blood agar plates at least four times, as
described previously (14). The inner surface of the catheter
tip was cultured by a modified quantitative method (11); 2 ml of Trypticase soy broth was passed across each lumen and was then
diluted 10-fold, and each dilution was plated onto blood agar. Colony
counting was carried out after incubation of the plates at 37°C in a
5% CO2 atmosphere for 48 h. Skin and catheter hub
cultures were considered positive when
15 CFU was isolated. The
criteria for positivity of the catheter tip culture were counts of
103 CFU by the quantitative method and counts of
15 CFU
by the roll-plate method. Blood cultures were performed by routine
methods (BACTEC NR 860 instrument; Johnston Laboratories, Inc., Towson,
Md.). The bacteria were fully identified by conventional procedures and
by an automated method (MicroScan; Baxter Healthcare, West Sacramento,
Calif.). Antibiotic susceptibility studies were performed by the disk
diffusion method and by the microdilution method.
Molecular typing.
Molecular typing was performed by
pulsed-field gel electrophoresis (PFGE) after DNA restriction with
SmaI and separation of fragments in a contour-clamped
homogeneous electric field (CHEF-DRII) apparatus (Bio-Rad, Richmond,
Calif.) with running conditions of 200 V and pulse times ranging from 1 to 30 s for 23 h at 14°C (3).
Definitions.
Significant colonization of the catheter hub
was defined as the isolation of
15 CFU. Bacteremia attributed to
luminal colonization was defined as the isolation of identical
organisms from the catheter hub and from cultures of separate
percutaneously drawn blood specimens; the organism's identity was
proven by molecular typing for patients with Staphylococcus
epidermidis bacteremia. Catheter occlusion was defined as the
inability to aspirate blood through the catheter and/or the inability
to force infusate through the catheter with usual infusion pressure.
Patients were considered to have a fever if the temperature was above
38°C.
Statistical analysis.
To assess the adequacy of
randomization, groups were compared by the uncorrected chi-square test
or, when appropriate, Fisher's exact test for categorical variables
and the Mann-Whitney test for continuous variables. The distributions
of time until catheter hub colonization and time until catheter-related
bacteremia were stimated by the Kaplan-Meier method and were compared
across the two groups by the log rank test (Mantel-Cox test). Crude and
adjusted hazard ratios could not be estimated because no events were
observed in the heparin and vancomycin group. However, since
randomization produced two groups of patients with comparable baseline
characteristics, no indication of positive or negative confounding
needed to be controlled for with multivariate Cox models. Statistical
significance was established at an alpha value of 0.05. All
P values are two-tailed.
The sample size of 116 patients was calculated to give an 80% power to
detect a 20% difference in the rate of catheter hub
colonization by
the two treatments at a one-sided 0.05 level of
significance. On the
basis of our previous experience (
11),
it was estimated that
about 25% of patients in the heparin group
would develop catheter hub
colonization. The effect of heparin
and vancomycin treatment was
thought to be clinically relevant
if the catheter hub colonization rate
was reduced to 5%. We performed
an intention-to-treat analysis for all
patients who received at
least one dose of study
solution.
 |
RESULTS |
We recruited 120 consecutive patients; 60 were randomly assigned
to receive heparin and 60 were randomly assigned to receive heparin and
vancomycin (Fig. 1). Three patients
assigned to receive heparin had to be withdrawn before receiving the
drug because of CoNS colonization of the catheter skin insertion site
and hub detected in baseline cultures (one patient), infection of knee prosthesis (one patient), and protocol violation (one patient). Overall, 57 patients received heparin and 60 patients received the
solution of heparin and vancomycin. The baseline characteristics of the
patients in each group were similar, and no significant differences
were found with regard to age, sex, and underlying disease (Table
1). The type of catheter and the mean
duration of catheterization prior to study inclusion were comparable
for the two treatment groups. Catheters remained in place while the patients were in the study for similar mean durations for each treatment group; 11 days for patients who received heparin and 10 days
for patients in the heparin and vancomycin group (P = 0.30) (Table 2). No catheter-related
infection was observed in patients receiving heparin and vancomycin.
Significant colonization of the catheter hub occurred in 9 (15.8%) of
57 patients treated with heparin but in none of 60 patients treated
with heparin and vancomycin (P = 0.001).
Catheter-related bacteremia occurred in 4 (7%) of 57 patients
receiving heparin but in none of the 60 patients receiving heparin and
vancomycin (P = 0.05). No colonization of the skin
insertion site was detected during the study period. Bacteremias not
attributable to catheter infection occurred at equal frequencies in
both treatment groups; 13 (22.8%) patients in the heparin group and 15 (25%) patients in the heparin and vancomycin group (P = 0.35). In all these patients, cultures of catheter hub and skin
insertion site swabs obtained at the time of bacteremia were negative.
Six (10.5%) patients receiving heparin had catheter occlusion, whereas
four (6.7%) of those receiving heparin and vancomycin had catheter
occlusion (P = 0.52); in all these patients the
catheter patency was reestablished by using heparin or urokinase
flushings. None of the patients died during the study. One patient who
had received heparin died of invasive pulmonary aspergillosis and one
patient who had received heparin and vancomycin died of uncontrolled
cancer 1 and 2 months after completion of the study, respectively.
The organisms that caused catheter hub colonization were S. epidermidis (n = 7 patients), Staphylococcus
capitis (n = 1), and Corynebacterium
sp. (n = 1), and those that caused catheter-related bacteremia were S. epidermidis (n = 3) and
S. capitis (n = 1). In each of the three
patients with catheter-related S. epidermidis bacteremia,
molecular typing by PFGE showed that the blood and hub isolates were
identical (Fig. 2). In one of these
patients the catheter had to be removed because of breakthrough
bacteremia, and the catheter tip grew the same strain. No
vancomycin-resistant organism was isolated from any source during the
study period.

View larger version (128K):
[in this window]
[in a new window]
|
FIG. 2.
PFGE of genomic DNAs of S. epidermidis
strains isolated from catheter segments and corresponding blood
cultures. Lanes 2 to 9 and 11 to 13 show that the S. epidermidis strains isolated from each patient had identical DNA
patterns. Lanes 1 and 10, bacteriophage lambda ladder PFGE marker (New
England, BioLabs, Beverly, Mass.).
|
|
Figure 3 shows Kaplan-Meier curves for
catheter hub colonization by treatment group. In the heparin and
vancomycin group, all patients remained free of catheter hub
colonization at the end of follow-up. In contrast, in the heparin
group, the proportion of patients free of colonization of the catheter
hub decreased to 74.6% at the end of the study. The survival
distributions compared by the log rank test were significantly
different (P = 0.004).
Figure 4 shows Kaplan-Meier curves for
catheter-related bacteremia by treatment group. In the heparin and
vancomycin group, all patients remained free of bacteremia at the end
of the study. Conversely, in the heparin group the proportion of
patients free of catheter-related bacteremia decreased to 88% at the
end of the study (P = 0.06).
 |
DISCUSSION |
Our prospective, randomized, double-blind trial shows that an ALT
with vancomycin can decrease the frequency of endoluminal catheter-related gram-positive bacterial infection during episodes of
chemotherapy-induced neutropenia in patients with hematologic malignancies.
Despite important advances in preventive measures (12, 13, 20-22,
26), catheter-related infection remains a significant clinical
problem in many institutions. Two randomized studies with children have
analyzed a preventive method of endoluminal catheter-related infection
based on catheter flushing, but they had conflicting results. Schwartz
et al. (25) used a solution of heparin and vancomycin to
flush tunneled CVCs and compared its efficacy with that of heparin
alone in 45 children with oncologic or hematologic disorders. Daily
flushing with heparin and vancomycin significantly decreased the
frequency of catheter-related bacteremia attributed to luminal
colonization with gram-positive organisms that were susceptible to
vancomycin. On the other hand, a recent randomized, open trial
(24) that included 55 children with cancer and 8 children
receiving total parenteral nutrition for bowel disorders found that
this flush solution had no effect on the risk of catheter-related
bacteremia caused by gram-positive bacteria. It should be noted that in
both studies neither surveillance cultures of the catheter hub nor
molecular typing of the organisms was performed. In addition, a flush
solution containing minocycline and EDTA has successfully been used to
prevent recurrent catheter infections in three patients with serious
diseases (19).
Our study involved 117 adult patients with hematologic malignancies and
was designed to prevent colonization of the catheter hub as the entry
point for microorganisms that lead to endoluminal catheter-related
bacteremia during neutropenia. We used an ALT which allows delivery of
a high concentration of the antibiotic inside the catheter lumen. By
this straightforward technique, colonization of the catheter hub and
catheter-related bacteremia of endoluminal origin were successfully
prevented. Previous data have shown that there is a link between the
number of organisms colonizing a catheter and the risk of infection
(27). As recently pointed out by Raad (17), most
catheters are colonized with organisms embedded in a biofilm, but
infection appears to depend on whether the organisms on the catheter
surface, particularly those in a planktonic free-floating phase, exceed
a certain quantitative threshold. Since biofilm bacteria are relatively
resistant to antibiotics, it can be speculated that our preventive ALT
eradicated the organisms soon after they were introduced into the hub
from the hands of sanitary personnel in some cases, while in others the
ALT probably interfered with the multiplication and release of
free-floating organisms.
Recently, the emergence and spread of vancomycin resistance among
gram-positive organisms have become matters of great concern (9,
16). A limitation of our study could be that the prophylactic use
of vancomycin could lead to the selection of such resistant organisms.
However, we believe that this possibility is unlikely. By using the
ALT, the drug is applied locally and does not come into contact with
patients' blood. It is administered at a high concentration rather
than at the subinhibitory concentrations that seem most prone to lead
to the emergence of resistance. Moreover, it is important that our
study involved patients with hematologic malignancies and that the ALT
with vancomycin was not used for the whole duration of catheterization.
It was applied only during episodes of chemotherapy-induced
neutropenia, when the risk of serious complications following
catheter-related bacteremia is particularly high (7, 23). In
the critically ill population described here, the increase in the
numbers of infections caused by gram-positive organisms observed in
many institutions, which has been related in part to a significant
increase in catheter-related infections (5), has led to the
widespread empirical use of systemic vancomycin.
In summary, our study demonstrates that a solution containing heparin
and vancomycin administered by using an ALT effectively prevents
colonization of the catheter hub and endoluminal catheter-related bacteremia during episodes of chemotherapy-induced neutropenia in
patients with hematologic malignancies. Furthermore, this prophylactic strategy can be used as a basis for conducting future randomized trials
with other classes of antibiotics.
 |
ACKNOWLEDGMENTS |
We are grateful to J. L. Pontón for preparing the
study solutions and M. A. Domínguez for performing the
molecular typing of organisms. We thank the nursing staff of the
Clinical Hematology Service for valuable cooperation.
This study was supported in part by grant 93/1081 from Fondo de
Investigación Sanitaria, Madrid, Spain.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Infectious
Disease Service, Hospital de Bellvitge, Feixa Llarga sn, 08907 L'Hospitalet, Barcelona, Spain. Phone: 34933357011, ext. 2487. Fax:
34932607637. E-mail: jcarratala{at}csub.scs.es.
 |
REFERENCES |
| 1.
|
Benoit, J. L.,
G. Carandang,
M. Sitrin, and P. M. Arnow.
1995.
Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home.
Clin. Infect. Dis.
21:1286-1288[Medline].
|
| 2.
|
Capdevila, J. A.,
J. Gavalda, and A. Pahissa.
1996.
Antibiotic-lock technique: usefulness and controversies.
Antimicrob. Infect. Dis. News.
15:9-13.
|
| 3.
|
Domínguez, M. A.,
J. Liñares,
A. Pulido,
J. L. Pérez, and H. De Lencastre.
1996.
Molecular tracking of coagulase-negative staphylococcal isolates from catheter-related infections.
Microb. Drug Resist.
2:423-429.
[Medline] |
| 4.
|
Eastridge, B. J., and A. T. Lefor.
1995.
Complications of indwelling venous access devices in cancer patients.
J. Clin. Oncol.
13:233-238[Abstract/Free Full Text].
|
| 5.
|
González-Barca, E.,
A. Fernández-Sevilla,
J. Carratalà,
A. Grañena, and F. Gudiol.
1996.
Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.
Eur. J. Clin. Microbiol. Infect. Dis.
15:291-296[Medline].
|
| 6.
|
Groeger, J. S.,
A. B. Lucas,
H. T. Thaler,
H. Friedlander-Klar,
A. E. Brown,
T. E. Kiehn, and D. Armstrong.
1993.
Infectious morbidity associated with long-term use of venous access devices in patients with cancer.
Ann. Intern. Med.
119:1168-1174[Abstract/Free Full Text].
|
| 7.
|
Guiot, H. F. L.,
L. G. Visser,
R. M. Y. Barge,
R. Bosboom, and J. A. M. van de Klunder.
1994.
Fatal meningitis due to catheter-related Staphylococcus epidermidis bacteraemia in a granulocytopenic patient without predisposing trauma.
Eur. J. Clin. Microbiol. Infect. Dis.
13:772-775[Medline].
|
| 8.
|
Henrickson, K. J.,
K. R. Powell, and C. L. Schwartz.
1988.
A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities.
J. Infect. Dis.
157:600-601[Medline].
|
| 9.
|
Hiramatsu, K.,
N. Aritaka,
H. Hanaki,
S. Kawasaki,
Y. Hosoda,
S. Hori,
Y. Fukuchi, and I. Kobayashi.
1997.
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin.
Lancet
350:1670-1673[Medline].
|
| 10.
|
Howell, P. B.,
P. E. Walters,
G. R. Donowitz, and B. M. Farr.
1995.
Risk factors for infection of adult patients with cancer who have tunnelled central venous catheters.
Cancer
75:1367-1375[Medline].
|
| 11.
|
Liñares, J.,
A. Sitges-Serra,
J. Garau,
J. L. Pérez, and R. Martin.
1985.
Pathogenesis of catheter sepsis: a prospective study with quantitative and semiquantitative cultures of catheter hub and segments.
J. Clin. Microbiol.
21:357-360[Abstract/Free Full Text].
|
| 12.
|
Maki, D. G.,
M. Ringer, and C. J. Alvarado.
1991.
Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters.
Lancet
338:339-343[Medline].
|
| 13.
|
Maki, D. G.,
S. M. Stolz,
S. Wheeler, and L. A. Mermel.
1997.
Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial.
Ann. Intern. Med.
127:257-266[Abstract/Free Full Text].
|
| 14.
|
Maki, D. G.,
C. E. Weise, and H. W. Sarafin.
1977.
A semiquantitative culture method for identifying intravenous catheter related infection.
N. Engl. J. Med.
296:1305-1309[Abstract].
|
| 15.
|
Messing, B.,
R. Man,
R. Colimon,
F. Thuillier, and M. Beliah.
1990.
Antibiotic-lock technique is an effective treatment of bacterial catheter-related sepsis during parenteral nutrition.
Clin. Nutr.
9:220-225[Medline].
|
| 16.
|
Murray, B. E.
1997.
Vancomycin-resistant enterococci.
Am. J. Med.
102:284-293[Medline].
|
| 17.
|
Raad, I.
1998.
Intravascular-catheter-related infections.
Lancet
351:893-898[Medline].
|
| 18.
|
Raad, I., and G. P. Bodey.
1992.
Infectious complications of indwelling vascular catheters.
Clin. Infect. Dis.
15:197-210[Medline].
|
| 19.
|
Raad, I.,
A. Buzaid,
J. Rhyne,
R. Hachem,
R. Darouiche,
H. Safar,
M. Albitar, and R. J. Sheretz.
1997.
Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections.
Clin. Infect. Dis.
25:149-151[Medline].
|
| 20.
|
Raad, I.,
R. Darouiche,
J. Dupuis,
D. Abi-Said,
A. Gabrielli,
R. Hachem,
M. Wall,
R. Harris,
J. Jones,
A. Buzaid,
C. Robertson,
S. Shenaq,
P. Curling,
T. Burke,
C. Ericson, and the Texas Medical Center Catheter Study Group.
1997.
Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial.
Ann. Intern. Med.
127:267-274[Abstract/Free Full Text].
|
| 21.
|
Raad, I.,
R. Darouiche,
R. Hachem,
M. Mansouri, and G. P. Bodey.
1996.
The broad-spectrum activity and efficacy of catheters coated with mynocicline and rifampin.
J. Infect. Dis.
173:418-424[Medline].
|
| 22.
|
Raad, I.,
D. C. Hohn,
B. J. Gilbreath,
N. Suleiman,
L. A. Hill,
P. A. Bruso,
K. Marts, and P. F. Mansfield.
1994.
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion.
Infect Control Hosp Epidemiol.
15:231-238[Medline].
|
| 23.
|
Raad, I.,
J. Narro,
A. Khan,
J. Tarrand,
S. Vartivarian, and G. P. Bodey.
1992.
Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients.
Eur. J. Clin. Microbiol. Infect. Dis.
11:675-682[Medline].
|
| 24.
|
Rackoff, W. R.,
M. Weiman,
D. Jakobowski,
R. Hirschl,
V. Stallings,
J. Bilodeau,
P. Danz,
L. Bell, and B. Lange.
1995.
A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children.
J. Pediatr.
127:147-151[Medline].
|
| 25.
|
Schwartz, C.,
K. J. Henrickson,
K. Roghmann, and K. Powell.
1990.
Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms.
J. Clin. Oncol.
8:1591-1597[Abstract].
|
| 26.
|
Segura, M.,
F. Alvarez-Lerma,
J. M. Tellado,
J. Jiménez-Ferreres,
L. Oms,
J. Rello,
T. Baró,
R. Sánchez,
A. Morera,
D. Mariscal,
J. Marrugat, and A. Sitges-Serra.
1996.
A clinical trial on the prevention of catheter-related sepsis using a new hub model.
Ann. Surg.
223:363-369[Medline].
|
| 27.
|
Sheretz, R. J.,
I. I. Raad,
A. Balani,
L. Koo, and K. Rand.
1990.
Three-year experience with sonicated vascular catheter cultures in a clinical microbiology laboratory.
J. Clin. Microbiol.
28:76-82[Abstract/Free Full Text].
|
| 28.
|
Tacconelli, E.,
M. Tumbarello,
M. Pittiruti,
F. Leone,
M. B. Lucia,
R. Cauda, and L. Ortona.
1997.
Central venous catheter-related sepsis in a cohort of 366 hospitalised patients.
Eur. J. Clin. Microbiol. Infect. Dis.
16:203-209[Medline].
|
| 29.
|
Tenney, J. H.,
M. R. Moody,
K. A. Newman,
S. C. Schimpff,
J. C. Wade,
J. W. Costerton, and W. P. Reed.
1986.
Adherent microorganisms on lumenal surfaces of long-term intravenous catheters. Importance of Staphylococcus epidermidis in patients with cancer.
Arch. Intern. Med.
146:1949-1954[Abstract/Free Full Text].
|
| 30.
|
Weightman, N. C.,
E. M. Simpson,
D. C. E. Speller,
M. G. Mott, and A. Oakhill.
1988.
Bacteraemia related to indwelling central venous catheters: prevention, diagnosis and treatment.
Eur. J. Clin. Microbiol. Infect. Dis.
7:125-129[Medline].
|
Antimicrobial Agents and Chemotherapy, September 1999, p. 2200-2204, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bookstaver, P B., Williamson, J. C, Tucker, B. K., Raad, I. I, Sherertz, R. J
(2009). Activity of Novel Antibiotic Lock Solutions in a Model Against Isolates of Catheter-Related Bloodstream Infections. The Annals of Pharmacotherapy
43: 210-219
[Abstract]
[Full Text]
-
Fennell, J. P., O'Donohoe, M., Cormican, M., Lynch, M.
(2008). Linezolid lock prophylaxis of central venous catheter infection. J Med Microbiol
57: 534-535
[Abstract]
[Full Text]
-
Vescia, S., Baumgartner, A. K., Jacobs, V. R., Kiechle-Bahat, M., Rody, A., Loibl, S., Harbeck, N.
(2008). Management of venous port systems in oncology: a review of current evidence. Ann Oncol
19: 9-15
[Abstract]
[Full Text]
-
Fortun, J., Grill, F., Martin-Davila, P., Blazquez, J., Tato, M., Sanchez-Corral, J., Garcia-San Miguel, L., Moreno, S.
(2006). Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother
58: 816-821
[Abstract]
[Full Text]
-
Fernandez-Hidalgo, N., Almirante, B., Calleja, R., Ruiz, I., Planes, A. M., Rodriguez, D., Pigrau, C., Pahissa, A.
(2006). Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother
57: 1172-1180
[Abstract]
[Full Text]
-
Sherertz, R. J., Boger, M. S., Collins, C. A., Mason, L., Raad, I. I.
(2006). Comparative in vitro efficacies of various catheter lock solutions.. Antimicrob. Agents Chemother.
50: 1865-1868
[Abstract]
[Full Text]
-
Ryder, M.
(2006). Evidence-Based Practice in the Management of Vascular Access Devices for Home Parenteral Nutrition Therapy. JPEN J Parenter Enteral Nutr
30: S82-S93
[Abstract]
[Full Text]
-
Garland, J. S., Alex, C. P., Henrickson, K. J., McAuliffe, T. L., Maki, D. G.
(2005). A Vancomycin-Heparin Lock Solution for Prevention of Nosocomial Bloodstream Infection in Critically Ill Neonates With Peripherally Inserted Central Venous Catheters: A Prospective, Randomized Trial. Pediatrics
116: e198-e205
[Abstract]
[Full Text]
-
Haase, K. K., McCracken, K. A., Akins, R. L.
(2005). Catheter-Related Bloodstream Infections in the Intensive Care Unit Population. Journal of Pharmacy Practice
18: 42-52
[Abstract]
-
Segarra-Newnham, M., Martin-Cooper, E. M
(2005). Antibiotic Lock Technique: A Review of the Literature. The Annals of Pharmacotherapy
39: 311-318
[Abstract]
[Full Text]
-
Rijnders, B. J., Van Wijngaerden, E., Vandecasteele, S. J., Stas, M., Peetermans, W. E.
(2005). Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother
55: 90-94
[Abstract]
[Full Text]
-
Kaufman, D., Fairchild, K. D.
(2004). Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants. Clin. Microbiol. Rev.
17: 638-680
[Abstract]
[Full Text]
-
Kite, P., Eastwood, K., Sugden, S., Percival, S. L.
(2004). Use of In Vivo-Generated Biofilms from Hemodialysis Catheters To Test the Efficacy of a Novel Antimicrobial Catheter Lock for Biofilm Eradication In Vitro. J. Clin. Microbiol.
42: 3073-3076
[Abstract]
[Full Text]
-
Raad, I., Chatzinikolaou, I., Chaiban, G., Hanna, H., Hachem, R., Dvorak, T., Cook, G., Costerton, W.
(2003). In Vitro and Ex Vivo Activities of Minocycline and EDTA against Microorganisms Embedded in Biofilm on Catheter Surfaces. Antimicrob. Agents Chemother.
47: 3580-3585
[Abstract]
[Full Text]
-
O'Grady, N. P., Alexander, M., Dellinger, E. P., Gerberding, J. L., Heard, S. O., Maki, D. G., Masur, H., McCormick, R. D., Mermel, L. A., Pearson, M. L., Raad, I. I., Randolph, A., Weinstein, R. A.
(2002). Guidelines for the Prevention of Intravascular Catheter-Related Infections. Pediatrics
110: e51-51
[Abstract]
[Full Text]
-
Raad, I., Hachem, R., Tcholakian, R. K., Sherertz, R.
(2002). Efficacy of Minocycline and EDTA Lock Solution in Preventing Catheter-Related Bacteremia, Septic Phlebitis, and Endocarditis in Rabbits. Antimicrob. Agents Chemother.
46: 327-332
[Abstract]
[Full Text]